Grant to Be Funded by the V Foundation to Early Career Investigator at The University of Kansas Cancer Center
The V Foundation for Cancer Research, a top-rated cancer research charity, is excited to announce a continued collaboration with the Kansas City Chiefs and The University of Kansas Health System to support critical cancer research. Last year, the collaboration awarded a $200,000 grant to Mary Markiewicz, Ph.D., at The University of Kansas Cancer Center for her research related to using the immune system clinically to destroy cancer.
“We are thrilled to continue a partnership that is making a significant impact in the Kansas City community,” said Norm Bowling, Chief Revenue Officer of the V Foundation. “It’s wonderful to work together with the Chiefs, The University of Kansas Health System and ESPN to accelerate cancer research and help those who are living with cancer.”
The Chiefs and the Hunt Family Foundation will contribute $50,000 in October, and The University of Kansas Cancer Center will raise $50,000; that $100,000 will be matched by the V Foundation for an Early Career Investigator Grant to be awarded to a researcher at The University of Kansas Cancer Center. The partnership will bring continued V Foundation resources to the Kansas City area as it funds an emerging researcher in the Chiefs’ community.
“We are so thankful to partner with the V Foundation and The University of Kansas Health System on a program that was able to impact a local cancer researcher at The University of Kansas Cancer Center last year. We are even more pleased to be a part of the team that will enable the grant to support the program for a second year in a row,” Kansas City Chiefs President Mark Donovan said. “The V Foundation provides remarkable resources for medical researchers and healthcare professionals, and we believe they are supporting the best in the field in their grant to The University of Kansas Cancer Center and their researchers.”
On Sunday, during the Chiefs Crucial Catch game, versus the Jacksonville Jaguars, the Hunt Family Foundation held a 50/50 raffle that raised more than $69,000 to help support funding efforts. Half of the net proceeds will go to The University of Kansas Cancer Center. Crucial Catch: Intercept Cancer aims to move the country towards unprecedented levels of early detection and risk reduction of screenable cancers and allows the NFL to reach and impact a wider population affected by various forms of cancer.
“By supporting The University of Kansas Cancer Center, we are fostering new therapies to fight cancer, providing new hope for patients, and investing in the health of the Kansas City community as well as this entire region,” said Bob Page, President and Chief Executive Officer of The University of Kansas Health System.
The V Foundation Early Career Investigator Grant will support a young tenure-track researcher early in her/his career by funding projects that are either laboratory-based fundamental research or translational research. Learn more about the 2017 grantee Mary Markiewicz, Ph.D., and her research here.
“I applaud the efforts of the V Foundation and the Kansas City Chiefs to advance The University of Kansas Cancer Center’s efforts to fight this terrible disease. We are deeply grateful for these funds,” said Dr. Roy Jensen, Director of The University of Kansas Cancer Center.
The partnership is part of ESPN’s Blitz Cancer campaign, which pairs the V Foundation with professional football teams to support all types of cancer research at NCI-designated cancer centers in team markets.
“This joint partnership with three incredible champions for good — the V Foundation, the Kansas City Chiefs, and The University of Kansas Cancer Center — demonstrates the power of working as ONE team to fight this terrible disease,” said Kevin Martinez, Vice President of ESPN Corporate Citizenship. “Together, we will BLITZ Cancer!”
For more information about the V Foundation, its grant program or to donate, please visit www.jimmyv.org.
Liso-Cel Shows Comparable Real-World Outcomes in Relapsed/Refractory LBCL
December 9th 2024Real-world treatment with liso-cel showed a broad spectrum of outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.